New drug combination passes safety test in pancreatic cancer

(Mary Ann Liebert, Inc./Genetic Engineering News) A new study has shown a novel peptide antagonist, given in combination with a PD-1 inhibitor, to be safe and well-tolerated in patients with advanced, refractory pancreatic and rectal cancer.